
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is a company with a diverse portfolio of lucrative royalty assets, a strong patent portfolio, and a promising pipeline of new products. Their recent acquisition and successful clinical trials have attracted investor interest and suggest potential for significant revenue growth. The company's solid financial position and strategic investments bode well for their future success and make it a recommended buy for investors.
Bears say
Innoviva is heavily reliant on the success of its new drugs, which may not live up to expectations. Additionally, the company's royalty portfolio is primarily focused on infectious diseases, which poses a risk if there is a decline in demand or change in treatment preferences. The acquisition of a new drug delivery technology is promising but also brings uncertainty and potential costs.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares